<DOC>
	<DOCNO>NCT01799057</DOCNO>
	<brief_summary>The purpose study determine effect metformin functional capacity ( pain-free maximum walk time ) individual peripheral artery disease ( PAD ) -related intermittent claudication .</brief_summary>
	<brief_title>The Effects Metformin Functional Capacity Individuals With Peripheral Artery Disease-Related Intermittent Claudication</brief_title>
	<detailed_description>Background Rationale : Metformin demonstrable efficacy slow reverse progression various insulin-resistant disease state - notably type 2 diabetes pre-diabetes . In seek establish proof-of-concept insulin resistance suitable pathophysiological target treatment PAD-related intermittent claudication ( pain leg muscle walk , resolve exercise cessation ) , study determine whether know insulin-sensitizing effect metformin translate alleviation functional limitation impose claudication . Study Design : A total 80 individual PAD-related intermittent claudication randomise ( 1:1 ) either metformin match placebo 16-18 week ( double-blind , parallel group design ) . The maximum daily dose metformin 2000mg ( up-titrated half dose 2 week tolerate ) . Primary Hypothesis : Improvement functional capacity follow metformin therapy individual PAD-related intermittent claudication . Change functional capacity assess co-primary endpoint pain-free maximum walk time standard grade treadmill exercise test . Secondary Aims : Exercise test functional performance complement assessment perceive physical functioning / quality life daily life setting ( use standard questionnaire ) . As previous study indicate cardiovascular effect metformin incremental blood glucose-lowering , study also investigate potential mechanism efficacy relate primary endpoint , include change endothelial function , blood flow responses various stimulus ( include insulin acute exercise ) , insulin sensitivity , physical activity / sedentary behaviour . Changes relevant clinical data ( include ankle-brachial index limb hemodynamics duplex scan ) also determine . Outcomes Significance : The unmet clinical need efficacious medical therapy intermittent claudication grow problem give increase prevalence PAD worldwide . If positive , study identify new potential treatment already widely available . The study also inform novel mechanistic target relevance exist future therapeutic strategy .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age ≥40 year old . Resting anklebrachial index ( ABI ) ≤0.90 limit leg ( ) , &gt; 20 % reduction ABI measure immediately postexercise rest ABI &gt; 0.90 . In case incompressible artery limit leg ( ) ( i.e . ABI ≥1.40 ) , toebrachial index ( TBI ) ≤0.70 require . Peripheral artery stenosis/occlusion limit leg ( ) , document duplex ultrasonography imaging test . Stable ( i.e . 3month history ) intermittent claudication least one PADaffected leg . Maximum walking time grade treadmill exercise testing ( GardnerSkinner protocol ) ≥1 minute ≤16 minute . Concurrent medication may affect primary , secondary exploratory endpoint remain stable previous 3 month . Have give sign informed consent participate study . Identification medical condition require immediate therapeutic intervention . Clinically significant abnormal electrocardiogram ( ECG ) rest exercise represent contraindication study procedure study drug . Myocardial infarction , unstable angina , percutaneous transluminal coronary angioplasty ( PTCA ) , coronary artery bypass graft surgery ( CABG ) , major surgery within previous 6 month . Exercise capacity limit factor PADrelated intermittent claudication . Any condition precludes valid completion treadmill exercise test . Critical limb ischemia either leg , define PADrelated chronic ischemic rest pain skin lesion ( ulcer , gangrene ) . Previous peripheral revascularisation surgical treatment PAD previous 6 month . Known nonatherosclerotic cause PAD . Active cancer . Uncontrolled hypertension ( rest brachial blood pressure ≥160/100 mmHg ) . Evidence pharmacologicallytreated poorly control ( i.e . HbA1c ≥7.5 % ) type 2 diabetes class diabetes ( e.g . type 1 diabetes ) . Known intolerance contraindication ( ) metformin . Known contraindication ( ) `` Definity '' ( perflutren lipid microsphere ) . Participation intention participate another clinical research study study period . History noncompliance medical regimen unwillingness comply study protocol . Any condition opinion Investigators would confound evaluation interpretation data . Persons directly involved execution protocol . Incapable provide write informed consent due cognitive , language , reason .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Intermittent Claudication</keyword>
	<keyword>Peripheral Vascular Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Glucose Metabolism</keyword>
	<keyword>Blood Glucose</keyword>
	<keyword>Metformin</keyword>
	<keyword>Biguanides</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Endothelium , Vascular</keyword>
	<keyword>Hemorheology</keyword>
	<keyword>Blood Circulation</keyword>
	<keyword>Regional Blood Flow</keyword>
	<keyword>Microcirculation</keyword>
	<keyword>Exercise</keyword>
	<keyword>Physical Fitness</keyword>
	<keyword>Exercise Test</keyword>
	<keyword>Sedentary Lifestyle</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Plethysmography</keyword>
</DOC>